Mohraz Minoo, Sedaghat Abbas, SeyedAlinaghi SeyedAhmad, Asheri Hossein, Mohammaddoust Saeid, Gharibdoost Farhad, Khorshid Hamid Reza Khorram, Farhadi Mohammad, Madani Seyed Hesamedin, Kamali Koorosh
Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Infect Disord Drug Targets. 2013 Feb;13(1):71-4. doi: 10.2174/18715265112129990031.
Acquired immune deficiency syndrome is one of the world's serious health problems. Immune-based therapy is a new approach in the treatment of HIV infected patients. IMOD™ with the ability to correct immune deficiencies has been introduced for the management of HIV infection. In the phase IV trial study the main objectives were to assess the possible side effects, evaluate its effect on CD4⁺ T lymphocyte count and patients' and physicians' satisfactions for 600 HIV infected patients in 13 centers during 2007. The observed adverse events in patients included: headache and vertigo (1.2%), nausea (1.2%), gastritis (1.2%), phlebitis (1%) and mild rash (1%); serious adverse events were not observed in any of IMOD™ recipients. Therefore it was not needed to terminate the treatment in any of patient. The results of this study demonstrated that daily prescription of IMOD™ significantly increases T lymphocyte CD4⁺ and total lymphocyte count in HIV-positive patients. In addition, nearly 90% of the patients and 70% physicians are satisfied by IMOD™ treatment.
获得性免疫缺陷综合征是全球严重的健康问题之一。基于免疫的疗法是治疗HIV感染患者的一种新方法。具有纠正免疫缺陷能力的IMOD™已被用于管理HIV感染。在IV期试验研究中，主要目标是评估600名HIV感染患者在2007年期间于13个中心使用IMOD™可能出现的副作用、评估其对CD4⁺T淋巴细胞计数的影响以及患者和医生的满意度。患者中观察到的不良事件包括：头痛和眩晕（1.2%）、恶心（1.2%）、胃炎（1.2%）、静脉炎（1%）和轻度皮疹（1%）；在任何接受IMOD™治疗的患者中均未观察到严重不良事件。因此，无需对任何患者终止治疗。该研究结果表明，每日服用IMOD™可显著提高HIV阳性患者的T淋巴细胞CD4⁺和总淋巴细胞计数。此外，近90%的患者和70%的医生对IMOD™治疗感到满意。
